Christo Cimino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christo Cimino has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Amanda Binkley
Department of Pharmacy; Penn Presbyterian Medical Center; Philadelphia Pennsylvania
1 shared publicationAnne H. Norris
Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
1 shared publicationBan M. Allos
Vanderbilt University Medical Center, Nashville, TN, USA
1 shared publication- Benjamin Colton
Pharmacy Department, National Institutes of Health Clinical Center , Bethesda, Maryland , USA
1 shared publication - Benjamin J. Ereshefsky
Vanderbilt University Medical Center
1 shared publication - Christina Grace Rivera
Mayo Clinic
1 shared publication
Latest Publications
- Open Access
- 10 December 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1)
Impact of institutional treatment guidance on the management and outcomes of Stenotrophomonas maltophilia and carbapenem-resistant Acinetobacter baumannii infections
Objective: To evaluate the impact of a guidance document on treatment decisions and clinical outcomes for infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and Stenotrophomonas maltophilia. Design: This was a single-center, retrospective, quasi-experimental, pre- and post-intervention study. The primary outcome was adherence to antibiotic selection and dosing as recommended by the guidance document. Secondary outcomes included clinical efficacy, readmission within 90 days, all-cause 30-day mortality, 90-day microbiologic recurrence, and antibiotic-associated adverse effects. Setting: The study was conducted at a large, academic medical center in the Southeastern United States. Participants: The study included adult patients who were admitted to our institution from November 2018 to June 2024 who grew CRAB or S. maltophilia from any culture and were definitively treated. Intervention: This study included an institution specific treatment algorithm for the treatment of infections caused by resistant gram-negative organisms published on June 1 st , 2022, on our institution’s antimicrobial stewardship website. Results: Twenty-two patients with CRAB (14 pre- and 8 post-intervention) and 150 with S. maltophilia (75 pre- and 75 post-intervention) were evaluated. For CRAB, 0 (0%) patients in the pre-intervention group and 5 (62.5%) in the post-intervention group met the primary outcome ( P < .001). For S. maltophilia, 21 (28%) patients in the pre-intervention group compared to 38 (50.7%) in the post-intervention group met the primary outcome ( P < .004). Secondary outcomes did not differ significantly pre- and post-intervention. Conclusions: These findings demonstrate that implementing a local treatment guideline based on IDSA guidance may increase the utilization of evidence-based directed antimicrobial therapy for CRAB and S. maltophilia.
- 10 December 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1)
Open AccessImpact of institutional treatment guidance on the management and outcomes of Stenotrophomonas maltophilia and carbapenem-resistant Acinetobacter baumannii infections
Objective: To evaluate the impact of a guidance document on treatment decisions and clinical outcomes for infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and Stenotrophomonas maltophilia. Design: This was a single-center, retrospective, quasi-experimental, pre- and post-intervention study. The primary outcome was adherence to antibiotic selection and dosing as recommended by the guidance document. Secondary outcomes included clinical efficacy, readmission within 90 days, all-cause 30-day mortality, 90-day microbiologic recurrence, and antibiotic-associated adverse effects. Setting: The study was conducted at a large, academic medical center in the Southeastern United States. Participants: The study included adult patients who were admitted to our institution from November 2018 to June 2024 who grew CRAB or S. maltophilia from any culture and were definitively treated. Intervention: This study included an institution specific treatment algorithm for the treatment of infections caused by resistant gram-negative organisms published on June 1 st , 2022, on our institution’s antimicrobial stewardship website. Results: Twenty-two patients with CRAB (14 pre- and 8 post-intervention) and 150 with S. maltophilia (75 pre- and 75 post-intervention) were evaluated. For CRAB, 0 (0%) patients in the pre-intervention group and 5 (62.5%) in the post-intervention group met the primary outcome ( P < .001). For S. maltophilia, 21 (28%) patients in the pre-intervention group compared to 38 (50.7%) in the post-intervention group met the primary outcome ( P < .004). Secondary outcomes did not differ significantly pre- and post-intervention. Conclusions: These findings demonstrate that implementing a local treatment guideline based on IDSA guidance may increase the utilization of evidence-based directed antimicrobial therapy for CRAB and S. maltophilia.
- Open Access
- 15 March 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (4) , ofae128
Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians
Nontuberculous mycobacteria (NTM) can cause a variety of infections, including serious pulmonary disease. Treatment encompasses polypharmacy, with a targeted regimen of 2–5 active medications, depending on site of infection, species, and clinical characteristics. Medications may include oral, intravenous, and inhalational routes. Medication acquisition can be challenging for numerous reasons, including investigational status, limited distribution models, and insurance prior authorization. Additionally, monitoring and managing adverse reactions and drug interactions is a unique skill set. While NTM is primarily medically managed, clinicians may not be familiar with the intricacies of medication selection, procurement, and monitoring. This review offers insights into the pharmacotherapeutic considerations of this highly complex disease state, including regimen design, medication acquisition, safety monitoring, relevant drug–drug interactions, and adverse drug reactions.
- 15 March 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (4) , ofae128
Open AccessPharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians
Nontuberculous mycobacteria (NTM) can cause a variety of infections, including serious pulmonary disease. Treatment encompasses polypharmacy, with a targeted regimen of 2–5 active medications, depending on site of infection, species, and clinical characteristics. Medications may include oral, intravenous, and inhalational routes. Medication acquisition can be challenging for numerous reasons, including investigational status, limited distribution models, and insurance prior authorization. Additionally, monitoring and managing adverse reactions and drug interactions is a unique skill set. While NTM is primarily medically managed, clinicians may not be familiar with the intricacies of medication selection, procurement, and monitoring. This review offers insights into the pharmacotherapeutic considerations of this highly complex disease state, including regimen design, medication acquisition, safety monitoring, relevant drug–drug interactions, and adverse drug reactions.
- Open Access
- 2 March 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e41
An app a day: Results of pre- and post-surveys of knowledge, attitudes, and practices (KAP) regarding antimicrobial stewardship principles among nurses who utilized a novel learning platform
Background: Nurses perform several functions that are integral for antimicrobial stewardship (AMS). However, nurses are underrepresented in research and underutilized in implementation of AMS interventions. The objective of this pilot study was to assess the effect of asynchronous microlearning on inpatient nursing staff knowledge, attitudes, and practices (KAP) regarding AMS principles. Methods: A team of pharmacists, physicians, and nurses developed 9 case-based, multiple-choice questions with accompanying educational explanations on associated AMS principles. One case was delivered to participants daily via an institutional web-based application (QuizTime). A KAP survey with 20 questions on a 5-point Likert scale was administered before and after the intervention. Survey results were compared using a Wilcoxon signed-rank test. Results: Participants’ mean survey score after the intervention demonstrated statistically significant improvement for 18 (90%) of 20 items compared to before the intervention. Participants’ confidence improved in key AMS activities: (1) differentiating between colonization and infection (mean difference, 0.63; P < .001), (2) identifying unnecessary urine cultures and inappropriate treatment of urinary tract infections (mean difference, 0.94; P < .001), (3) recognizing opportunities for intravenous to oral therapy conversion (mean difference, 1.07; P < .001), and (4) assessing for antibiotic-associated adverse effects (mean difference, 0.54; P < .001). Conclusions: Nursing education provided through an asynchronous, microlearning format via a mobile platform resulted in statistically significant improvement in most KAP topics. Nurses are integral members of a multidisciplinary AMS team, and novel education methods can help equip them with the necessary AMS tools. This pilot study forms the basis for expanded AMS educational efforts in all healthcare professionals.
- 2 March 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e41
Open AccessAn app a day: Results of pre- and post-surveys of knowledge, attitudes, and practices (KAP) regarding antimicrobial stewardship principles among nurses who utilized a novel learning platform
Background: Nurses perform several functions that are integral for antimicrobial stewardship (AMS). However, nurses are underrepresented in research and underutilized in implementation of AMS interventions. The objective of this pilot study was to assess the effect of asynchronous microlearning on inpatient nursing staff knowledge, attitudes, and practices (KAP) regarding AMS principles. Methods: A team of pharmacists, physicians, and nurses developed 9 case-based, multiple-choice questions with accompanying educational explanations on associated AMS principles. One case was delivered to participants daily via an institutional web-based application (QuizTime). A KAP survey with 20 questions on a 5-point Likert scale was administered before and after the intervention. Survey results were compared using a Wilcoxon signed-rank test. Results: Participants’ mean survey score after the intervention demonstrated statistically significant improvement for 18 (90%) of 20 items compared to before the intervention. Participants’ confidence improved in key AMS activities: (1) differentiating between colonization and infection (mean difference, 0.63; P < .001), (2) identifying unnecessary urine cultures and inappropriate treatment of urinary tract infections (mean difference, 0.94; P < .001), (3) recognizing opportunities for intravenous to oral therapy conversion (mean difference, 1.07; P < .001), and (4) assessing for antibiotic-associated adverse effects (mean difference, 0.54; P < .001). Conclusions: Nursing education provided through an asynchronous, microlearning format via a mobile platform resulted in statistically significant improvement in most KAP topics. Nurses are integral members of a multidisciplinary AMS team, and novel education methods can help equip them with the necessary AMS tools. This pilot study forms the basis for expanded AMS educational efforts in all healthcare professionals.
- 16 February 2021
- Published by Springer Nature in Drugs
- Vol. 81 (5) , 555-574
Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis
Patients with end-stage renal disease (ESRD) requiring intermittent hemodialysis (IHD) are at increased risk of infection, which represents a leading cause of mortality in this population. The use of additional vascular access devices such as peripherally inserted central catheters to treat such infections should be minimized in patients with ESRD requiring IHD in order to mitigate complications such as infection and thrombosis and to maintain venous patency for hemodialysis access. Intravenous antimicrobial dosing following IHD has the advantages of avoiding additional access devices and providing convenience for patients and providers. Vancomycin, cefazolin, and aminoglycosides have historically been regarded as the primary intravenous antimicrobials administered with IHD given their relatively low cost, convenient dosing, and longevity of clinical use. Despite this, a growing body of literature is evaluating the use of an expanded list of antimicrobials that may be employed using post-dialysis dosing for patients requiring IHD; however, the available data are largely limited to pharmacokinetic studies and small cohorts of infected patients or uninfected subjects. Post-dialytic dosing of intravenous antimicrobials may be considered on a patient-by-patient basis after careful consideration of clinical, microbiological, and logistical factors that may influence the probability of treatment success. This document reviews and evaluates currently available information on the post-dialytic administration of an expanded list of intravenous antimicrobials in the setting of thrice-weekly, high-flux IHD.
- 16 February 2021
- Published by Springer Nature in Drugs
- Vol. 81 (5) , 555-574
Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis
Patients with end-stage renal disease (ESRD) requiring intermittent hemodialysis (IHD) are at increased risk of infection, which represents a leading cause of mortality in this population. The use of additional vascular access devices such as peripherally inserted central catheters to treat such infections should be minimized in patients with ESRD requiring IHD in order to mitigate complications such as infection and thrombosis and to maintain venous patency for hemodialysis access. Intravenous antimicrobial dosing following IHD has the advantages of avoiding additional access devices and providing convenience for patients and providers. Vancomycin, cefazolin, and aminoglycosides have historically been regarded as the primary intravenous antimicrobials administered with IHD given their relatively low cost, convenient dosing, and longevity of clinical use. Despite this, a growing body of literature is evaluating the use of an expanded list of antimicrobials that may be employed using post-dialysis dosing for patients requiring IHD; however, the available data are largely limited to pharmacokinetic studies and small cohorts of infected patients or uninfected subjects. Post-dialytic dosing of intravenous antimicrobials may be considered on a patient-by-patient basis after careful consideration of clinical, microbiological, and logistical factors that may influence the probability of treatment success. This document reviews and evaluates currently available information on the post-dialytic administration of an expanded list of intravenous antimicrobials in the setting of thrice-weekly, high-flux IHD.
- 20 November 2020
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 55 (8) , 1037-1049
A Review of β-Lactam–Associated Neutropenia and Implications for Cross-reactivity
To review the incidence, management, and current understanding of the pathophysiology of β-lactam–induced neutropenia and to critically evaluate the practicality and safety of direct substitution to an alternative β-lactam in the setting of this reaction. A literature analysis using the PubMed and Ovid search engines (July 1968 to October 2020) was performed using the search terms neutropenia, leukopenia, β-lactam, nonchemotherapy, agranulocytosis, and G-CSF (granulocyte colony-stimulating factor). The included English-language studies evaluated the incidence, mechanism, and/or management of β-lactam–induced neutropenia in pediatric or adult patients. Drug-induced neutropenia is a well-documented adverse reaction of β-lactam antibiotics, with an incidence of approximately 10% following at least 2 weeks of intravenous therapy. However, multiple gaps in knowledge remain in the mechanism of pathophysiology and optimal management of this reaction. Both direct toxic and immune-mediated mechanisms have been implicated. Although the cornerstone of management includes cessation of the offending agent, controversy exists on the appropriateness of direct substitution or future use of an alternative β-lactam. Given the frequency of use and superiority of β-lactams over alternative therapy for several infectious disease states, practical recommendations are needed on the management and safe use of β-lactams following β-lactam–induced neutropenia. Future use of β-lactams with differing R1 side chains, particularly those from a separate class, should not be deemed contraindicated following β-lactam–induced neutropenia and may be considered when indicated, with close laboratory monitoring.
- 20 November 2020
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 55 (8) , 1037-1049
A Review of β-Lactam–Associated Neutropenia and Implications for Cross-reactivity
To review the incidence, management, and current understanding of the pathophysiology of β-lactam–induced neutropenia and to critically evaluate the practicality and safety of direct substitution to an alternative β-lactam in the setting of this reaction. A literature analysis using the PubMed and Ovid search engines (July 1968 to October 2020) was performed using the search terms neutropenia, leukopenia, β-lactam, nonchemotherapy, agranulocytosis, and G-CSF (granulocyte colony-stimulating factor). The included English-language studies evaluated the incidence, mechanism, and/or management of β-lactam–induced neutropenia in pediatric or adult patients. Drug-induced neutropenia is a well-documented adverse reaction of β-lactam antibiotics, with an incidence of approximately 10% following at least 2 weeks of intravenous therapy. However, multiple gaps in knowledge remain in the mechanism of pathophysiology and optimal management of this reaction. Both direct toxic and immune-mediated mechanisms have been implicated. Although the cornerstone of management includes cessation of the offending agent, controversy exists on the appropriateness of direct substitution or future use of an alternative β-lactam. Given the frequency of use and superiority of β-lactams over alternative therapy for several infectious disease states, practical recommendations are needed on the management and safe use of β-lactams following β-lactam–induced neutropenia. Future use of β-lactams with differing R1 side chains, particularly those from a separate class, should not be deemed contraindicated following β-lactam–induced neutropenia and may be considered when indicated, with close laboratory monitoring.
- Open Access
- 15 August 2018
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 43 (6) , 757-767
Antiretroviral considerations in HIV-infected patients undergoing bariatric surgery
- 15 August 2018
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 43 (6) , 757-767
Open AccessAntiretroviral considerations in HIV-infected patients undergoing bariatric surgery